Tanshinol alleviates ulcerative colitis by promoting the expression of <scp>VLDLR</scp>

Zhu, Huanhuan; Tong, Shaopeng; Cui, Yan; Wang, Xiaodong; Wang, Minying

doi:10.1002/ddr.21840

Cited by 9 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 34 Also, one study demonstrated the anti-inflammatory role of VLDLR in the dextran sodium sulfate-induced mouse colitis model, which suggested a possible association in patients with IBD. 35 …”

Section: Discussionmentioning

confidence: 99%

New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases

Park,

Kim

et al. 2024

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Notably, 5-aminosalicylates (5-ASA) are vital in treating inflammatory bowel diseases (IBD). The adverse events of 5-ASA rarely occur but they could be fatal. Objectives: We aimed to discover new genetic biomarkers predicting 5-ASA-induced adverse events in patients with IBD. Design: This was a retrospective observational study. Methods: We performed a genome-wide association study on patients with IBD in South Korea. We defined subset 1 as 39 all adverse events and 272 controls; subset 2 as 20 severe adverse events and 291 controls (mild adverse events and control); subset 3 as 20 severe adverse events and 272 controls; and subset 4 as 19 mild adverse events and 272 controls. Logistic regression analysis was performed and commonly found associated genes were determined as candidate single-nucleotide polymorphisms predicting 5-ASA adverse events. Results: Patients with Crohn’s disease (CD) were significantly negatively associated with the development of adverse events compared to patients with ulcerative colitis (UC) (5.3% versus 22.9%). However, sex and age at diagnosis were unassociated with the adverse events of 5-ASA. rs13898676 [odds ratio (OR), 20.33; 95% confidence interval (CI), 5.69–72.67; p = 3.57 × e−6], rs12681590 (OR, 7.35; 95% CI, 2.85–19.00; p = 3.78 × e−5), rs10967320 (OR, 4.51; 95% CI, 2.18–9.31; p = 4.72 × e−5), and rs78726924 (OR, 3.54; 95% CI, 1.69–7.40; p = 7.96 × e−5) were genetic biomarkers predicting 5-ASA-induced severe adverse events in patients with IBD. Conclusion: The adverse events of 5-ASA were more common in patients with UC than those with CD in our study. We found that novel rs13898676 nearby WSB2 was the most significant genetic locus contributing to 5-ASA’s adverse event risk.

show abstract

Section: Discussionmentioning

confidence: 99%

New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases

Park,

Kim

et al. 2024

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Zhu et al used TAN (15.30 mg/kg) to intervene in DSS-induced UC mice for 14 days without setting a positive control group. The results showed that TAN was able to downregulate the activities of Caspase-3 and Caspase-9, inhibit the inflammatory levels of TNF-α, IL-6, IL-8IL-1β, and upregulate the expression of anti-apoptotic protein Bcl-2, which effectively inhibited endogenous apoptotic signaling, and alleviated the structural tissue destruction of colonic tissues and infiltration of inflammatory factors to a certain extent in UC mice (Zhu et al, 2021). The above findings suggest that all these compounds can modulate endogenous mitochondrial pathways, such as the anti-apoptotic protein Bcl-2, to achieve the treatment of UC, and such drugs may be candidates for the treatment of UC in the future.…”

Section: Compounds Related To Bcl-2 Signaling Pathwaymentioning

confidence: 99%

Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review

Chen,

Dong,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a nonspecific inflammatory bowel disease characterized by abdominal pain, bloody diarrhea, weight loss, and colon shortening. However, UC is difficult to cure due to its high drug resistance rate and easy recurrence. Moreover, long-term inflammation and increased disease severity can lead to the development of colon cancer in some patients. Programmed cell death (PCD) is a gene-regulated cell death process that includes apoptosis, autophagy, necroptosis, ferroptosis, and pyroptosis. PCD plays a crucial role in maintaining body homeostasis and the development of organs and tissues. Abnormal PCD signaling is observed in the pathological process of UC, such as activating the apoptosis signaling pathway to promote the progression of UC. Targeting PCD may be a therapeutic strategy, and natural compounds have shown great potential in modulating key targets of PCD to treat UC. For instance, baicalin can regulate cell apoptosis to alleviate inflammatory infiltration and pathological damage. This review focuses on the specific expression of PCD and its interaction with multiple signaling pathways, such as NF-κB, Nrf2, MAPK, JAK/STAT, PI3K/AKT, NLRP3, GPX4, Bcl-2, etc., to elucidate the role of natural compounds in targeting PCD for the treatment of UC. This review used (ulcerative colitis) (programmed cell death) and (natural products) as keywords to search the related studies in PubMed and the Web of Science, and CNKI database of the past 10 years. This work retrieved 72 studies (65 from the past 5 years and 7 from the past 10 years), which aims to provide new treatment strategies for UC patients and serves as a foundation for the development of new drugs.

show abstract

“…TNF-α 25 Chen, 2005;Chen, 2018;Deng, 2016;Du, 2019;Fan, 2022;Guo, 2018;Li, 2016;Li, 2019;Liang, 2017;Li and Tian, 2019;Peng, 2020;Su, 2021;Wang, 2018b;Wang, 2020a;Wang, 2022;Wu, 2021b;Xiong and Wang, 2016;Xu, 2020;Zhang, 2020;Zhou, 2017;Zhu, 2018;Zhu, 2019;Zhu, 2021;Zhu,2022 effective rate 22 Chen, 2018;Deng, 2016;Du, 2019;Li, 2016;Li, 2019;Liang, 2017;Li and Tian, 2019;Liu, 2011;Liu, 2018;Sun, 2019;Wang, 2018a;Wang, 2020a;Wang, 2020b;Wang, 2022;Xin, 2015;Xu, 2015;Xu, 2020;Yang and Wang, 2017;Zhang, 2020;Zhao, 2021;Zhu, 2018;Zhu, 2019IL-6 20 Chen, 2018Deng, 2016;<...…”

Section: Outcomes Number Studiesunclassified

A systematic review and meta-analysis of Danshen combined with mesalazine for the treatment of ulcerative colitis

Zhang,

Xiong,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Purpose: Current pharmacological treatments for Ulcerative Colitis (UC) have limitations. Therefore, it is important to elucidate any available alternative or complementary treatment, and Chinese herbal medicine shows the potential for such treatment. As a traditional Chinese herbal medicine, Danshen-related preparations have been reported to be beneficial for UC by improving coagulation function and inhibiting inflammatory responses. In spite of this, the credibility and safety of this practice are incomplete. Therefore, in order to investigate whether Danshen preparation (DSP) is effective and safe in the treatment of UC, we conducted a systematic review and meta-analysis.Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Database and CQVIP Database were searched for this review.The main observation indexes were the effect of DSP combined with mesalazine or DSP on the effective rate, platelet count (PLT), mean platelet volume (MPV) and C-reactive protein (CRP) of UC. The Cochrane risk of bias tool was used to assess the risk of bias. The selected studies were evaluated for quality and data processing using RevMan5.4 and Stata17.0 software.Results: A total of 37 studies were included. Among them, 26 clinical trials with 2426 patients were included and 11 animal experimental studies involving 208 animals were included. Meta-analysis results showed that compared with mesalazine alone, combined use of DSP can clearly improve the clinical effective rate (RR 0.86%, 95% CI:0.83–0.88, p < 0.00001) of UC. Furthermore it improved blood coagulation function by decreasing serum PLT and increasing MPV levels, and controlled inflammatory responses by reducing serum CRP, TNF-α, IL-6, and IL-8 levels in patients.Conclusion: Combining DSP with mesalazine for UC can enhance clinical efficacy. However, caution should be exercised in interpreting the results of this review due to its flaws, such as allocation concealment and uncertainty resulting from the blinding of the study.Systematic Review Registration: http://www.crd.york.ac.uk/PROSPERO/myprospero.php, identifier PROSPERO: CRD42022293287

show abstract

Tanshinol alleviates ulcerative colitis by promoting the expression of VLDLR

Cited by 9 publications

References 31 publications

New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases

New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases

Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review

A systematic review and meta-analysis of Danshen combined with mesalazine for the treatment of ulcerative colitis

Contact Info

Product

Resources

About